Cyclo Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6714 NW 16th St Ste B, Gainesville, Flor...Phone Number
(386) 418-8060Website
www.cyclotherapeutics.comRevenue
<$5 MillionStock Symbol
CYTHIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.Explore more
Cyclo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyclo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cyclo Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Cyclo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cyclo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Cyclo Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Cyclo Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cyclo Therapeutics
Product Launch: Get notified when Cyclo Therapeutics launches new products
Earning: See what the market has to say on Cyclo Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cyclo Therapeutics
Compare insights from companies similar to Cyclo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cyclo Therapeutics
<$5M
1-10
Public
$16.7M
1990
FM
Ffpm MullenInterim Chief Medical Officer, Cyclo Therapeutics
Company Profile Activity
Activity Insights
Cyclo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cyclo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cyclo Therapeutics.
Cyclo Therapeutics financials insights
Gather financial insights about Cyclo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$11.7M
2023
Share Placement
$5M
Cyclo Therapeutics Tech Stack
A closer look at the technologies used by Cyclo Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Data Management, Medical Research, Clinical Operations, Operations
Earnings
Inventory Management, Clinical Operations, Operations
Earnings
Business Development, Medical Research, Clinical Operations, Operations, Regulations
Earnings
Financial Planning, Sales, Financial Reporting, Operations, Revenue Operations, Risk
Cyclo Therapeutics News & Media
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan.Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysisRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysisCYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company’s shareholders. If you would like to discuss
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyclo Therapeutics
Sign Up For FreeTo access detailed company insights
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.... Read More
